The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders

Complementary Therapies in Medicine

Volumn 20, Issue 6, 2012, Pages 466-474

  Yang, Clinton W ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Cancer; Coronary heart disease; Diabetes; Dyslipidemia; Myocardial infarction; Osteoporosis; Red yeast rice; Statins

Indexed keywords

CHOLESTEROL; CHOLESTIN; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; XUEZHIKANG;

CARDIOVASCULAR MORTALITY; CHINESE MEDICINE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MEMORY DISORDER; MONASCUS PURPUREUS; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); MYALGIA; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONFATAL HEART INFARCTION; OSTEOPOROSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; SIDE EFFECT; TOXIC HEPATITIS; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL AGENTS; CAUSE OF DEATH; CHOLESTEROL; CORONARY DISEASE; DYSLIPIDEMIAS; HUMANS; HYPERCHOLESTEROLEMIA; MONASCUS; MYOCARDIAL INFARCTION;

EID: 84868479379     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2012.07.004     Document Type: Review

References (60)

1. Erdogrul O., Azirak S. A review on the red yeast rice (Monascus purpureus). KSU Journal of Science and Engineering 2005, 8:10-15.
2. Monograph Monascus purpureus (red yeast rice). Alternative Medicine Review 2004, 9:208-210.
3. Heber D., Yip I., Ashley J.M., Elashoff D.A., Elashoff R.M., Go V.L. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. American Journal of Clinical Nutrition 1999, 69:231-236.
4. Journoud M., Jones P.J. Red yeast rice: a new hypolipidemic drug. Life Sciences 2004, 74:2675-2683.
5. Liu J., Zhang J., Shi Y., Grimsgaard S., Alraek T., Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine 2006, 1:4.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA: The Journal of the American Medical Association 2001;285:2486-97.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine 1998;339:1349-57.
9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. New England Journal of Medicine 1996, 335:1001-1009.
10. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovascular Drugs and Therapy 2005, 19:403-414.
11. Kashani A., Phillips C.O., Foody J.M., Wang Y., Mangalmurti S., Ko D.T., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
12. Hansen K.E., Hildebrand J.P., Ferguson E.E., Stein J.H. Outcomes in 45 patients with statin-associated myopathy. Archives of Internal Medicine 2005, 165:2671-2676.
13. Kelly J.P., Kaufman D.W., Kelley K., Rosenberg L., Anderson T.E., Mitchell A.A. Recent trends in use of herbal and other natural products. Archives of Internal Medicine 2005, 165:281-286.
14. Halbert S.C., French B., Gordon R.Y., Farrar J.T., Schmitz K., Morris P.B., et al. Tolerability of red yeast rice (2,400mg twice daily) versus pravastatin (20mg twice daily) in patients with previous statin intolerance. American Journal of Cardiology 2010, 105:198-204.
15. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. Journal of Antibiotics 1979, 32:852-854.
16. Malinowski J.M., Gehret M.M. Phytosterols for dyslipidemia. American Journal of Health-System Pharmacy 2010, 67:1165-1173.
17. Zdrenghea D., Pop D., Colcear D. Effect of dietary isoflavones on plasma cholesterol. Romanian Journal of Internal Medicine 2006, 44:353-363.
18. Ma J., Li Y., Ye Q., Li J., Hua Y., Ju D., et al. Constituents of red yeast rice, a traditional Chinese food and medicine. Journal of Agricultural and Food Chemistry 2000, 48:5220-5225.
19. Zhu Y., Li C., Wang Y. Effects of Xuezhikang on blood lipids and lipoprotein concentrations of rabbits and quails with hyperlipidemia. Chinese Journal of Pharmacology 1995, 30:4-8.
20. Bogsrud M.P., Ose L., Langslet G., Ottestad I., Strom E.C., Hagve T.A., et al. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scandinavian Cardiovascular Journal 2010, 44:197-200.
21. Lin C.C., Li T.C., Lai M.M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. European Journal of Endocrinology/European Federation of Endocrine Societies 2005, 153:679-686.
22. Becker D.J., Gordon R.Y., Halbert S.C., French B., Morris P.B., Rader D.J. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of Internal Medicine 2009, 150(830-839):W147-W839.
23. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA: The Journal of the American Medical Association 1998, 279:1615-1622.
24. Moghadasian M.H., Frohlich J.J. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. American Journal of Medicine 1999, 107:588-594.
25. Jeon T., Hwang S.G., Hirai S., Matsui T., Yano H., Kawada T., et al. Red yeast rice extracts suppress adipogenesis by down-regulating adipogenic transcription factors and gene expression in 3T3-L1 cells. Life Sciences 2004, 75:3195-3203.
26. Becker D.J., Gordon R.Y., Morris P.B., Yorko J., Gordon Y.J., Li M., et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clinic Proceedings 2008, 83:758-764.
27. Kris-Etherton P.M., Harris W.S., Appel L.J. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23:151-152.
28. Cicero A.F., Brancaleoni M., Laghi L., Donati F., Mino M. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complementary Therapies in Medicine 2005, 13:273-278.
29. Marinangeli C.P., Jones P.J., Kassis A.N., Eskin M.N. Policosanols as nutraceuticals: fact or fiction. Critical Reviews in Food Science and Nutrition 2010, 50:259-267.
30. Perry C.M. Extended-release niacin (nicotinic acid)/laropiprant. Drugs 2009, 69:1665-1679.
31. Meador B.M., Huey K.A. Statin-associated myopathy and its exacerbation with exercise. Muscle and Nerve 2010, 42:469-479.
32. Andrus M.R., East J. Use of statins in patients with chronic hepatitis C. Southern Medical Journal 2010, 103:1018-1022. [quiz 1023].
33. Roselle H., Ekatan A., Tzeng J., Sapienza M., Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Annals of Internal Medicine 2008, 149:516-517.
34. Lu Z.L. China coronary secondary prevention study (CCSPS). Zhonghua Xin Xue Guan Bing Za Zhi 2005, 33:109-115.
35. Li J.J., Lu Z.L., Kou W.R., Chen Z., Wu Y.F., Yu X.H., et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Journal of Clinical Pharmacology 2009, 49:947-956.
36. Li J.J., Lu Z.L., Kou W.R., Chen Z., Wu Y.F., Yu X.H., et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Annals of Medicine 2010, 42:231-240.
37. Ye P., Lu Z.L., Du B.M., Chen Z., Wu Y.F., Yu X.H., et al. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. Journal of the American Geriatrics Society 2007, 55:1015-1022.
38. Zhao S.P., Lu Z.L., Du B.M., Chen Z., Wu Y.F., Yu X.H., et al. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). Journal of Cardiovascular Pharmacology 2007, 49:81-84.
39. Lee E., Ryan S., Birmingham B., Zalikowski J., March R., Ambrose H., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clinical Pharmacology and Therapeutics 2005, 78:330-341.
40. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
41. Benfante R., Reed D., Frank J. Do coronary heart disease risk factors measured in the elderly have the same predictive roles as in the middle aged Comparisons of relative and attributable risks. Annals of Epidemiology 1992, 2:273-282.
42. Thomas J.E., Tershakovec A.M., Jones-Burton C., Sayeed R.A., Foody J.M. Lipid lowering for secondary prevention of cardiovascular disease in older adults. Drugs and Aging 2010, 27:959-972.
43. Lin C.P., Chen Y.H., Chen J.W., Leu H.B., Liu T.Z., Liu P.L., et al. Cholestin (Monascus purpureus rice) inhibits homocysteine-induced reactive oxygen species generation, nuclear factor-kappaB activation, and vascular cell adhesion molecule-1 expression in human aortic endothelial cells. Journal of Biomedical Science 2008, 15:183-196.
44. Wang W.H., Zhang H., Yu Y.L., Ge Z., Xue C., Zhang P. Intervention of xuezhikang on patients of acute coronary syndrome with different levels of blood lipids. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004, 24:1073-1076.
45. Zhao S.P., Liu L., Cheng Y.C., Shishehbor M.H., Liu M.H., Peng D.Q., et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004, 110:915-920.
46. Pyorala K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes/Metabolism Reviews 1987, 3:463-524.
47. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine 1998, 339:229-234.
48. Chang J.C., Wu M.C., Liu I.M., Cheng J.T. Plasma glucose-lowering action of Hon-Chi in streptozotocin-induced diabetic rats. Hormone and Metabolic Research 2006, 38:76-81.
49. Fang Y., Li W. Effect of Xuezhikang on lipid metabolism and islet b cell function in type II diabetes mellitus patients. Journal of Capital Medicine 2000, 7:44-45.
50. Gutierrez G.E. Red yeast rice stimulates bone formation in rats. Nutrition Research 2006, 26:124-129.
51. Wong R.W., Rabie B. Chinese red yeast rice (Monascus purpureus-fermented rice) promotes bone formation. Chinese Medicine 2008, 3:4.
52. Hong X.Z., Li L.D., Wu L.M. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clinical and Experimental Pharmacology and Physiology 2007, 34:27-35.
53. Wang J.J., Shieh M.J., Kuo S.L., Lee C.L., Pan T.M. Effect of red mold rice on antifatigue and exercise-related changes in lipid peroxidation in endurance exercise. Applied Microbiology and Biotechnology 2006, 70:247-253.
54. Lee C.L., Kuo T.F., Wang J.J., Pan T.M. Red mold rice ameliorates impairment of memory and learning ability in intracerebroventricular amyloid beta-infused rat by repressing amyloid beta accumulation. Journal of Neuroscience Research 2007, 85:3171-3182.
55. Lee B.H., Ho B.Y., Wang C.T., Pan T.M. Red mold rice promoted antioxidase activity against oxidative injury and improved the memory ability of zinc-deficient rats. Journal of Agricultural and Food Chemistry 2009, 57:10600-10607.
56. Lee C.L., Wang J.J., Pan T.M. Red mold rice extract represses amyloid beta peptide-induced neurotoxicity via potent synergism of anti-inflammatory and antioxidative effect. Applied Microbiology and Biotechnology 2008, 79:829-841.
57. Tsai R.L., Ho B.Y., Pan T.M. Red mold rice mitigates oral carcinogenesis in 7,12-dimethyl-1,2-benz[a]anthracene-induced oral carcinogenesis in hamster. Evidence-based Complementary and Alternative Medicine 2011, 2011. 245209.
58. Hong M.Y., Seeram N.P., Zhang Y., Heber D. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. The Journal of Nutritional Biochemistry 2008, 19:448-458.
59. Gordon R.Y., Cooperman T., Obermeyer W., Becker D.J. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!. Archives of Internal Medicine 2010, 170:1722-1727.
60. Natural Standard: The Authority on Integrative Medicine; 2012. Available from: [accessed 26.06.12]. http://www.naturalstandard.com/.